Release No 19/2010 Affitech investor Trans Nova Investments is granted an exemption from the obligation to make a public offer to acquire the remaining shares of Affitech A/S * Affitech A/S' majority investor Trans Nova Investments Limited, who owns 53.3% of Affitech A/S' shares has received an exemption from the Danish Financial Supervisory Authority from the obligation to make a public offer to all shareholders to acquire the remaining shares of Affitech A/S Copenhagen and Oslo 26th May, 2010 Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today announced on behalf of Affitech A/S and its majority investor Trans Nova Investments Limited (“Trans Nova”), who owns 53.3% of the shares in Affitech A/S, that Trans Nova today by the Danish Financial Supervisory Authority has been granted an exemption from the obligation to make a public offer to all shareholders to acquire the remaining shares of Affitech A/S. Consequently, no such offer will be made by Trans Nova. Reference is made to Affitech A/S' Company Announcement No 8/2010 of 21 April 2010. -------------------------------------------------------------------------------- | For more information please contact: | -------------------------------------------------------------------------------- | | | Affitech A/S: | | | | Randi Krogsgaard, Corporate Communications and IR | | Tel # +45 2320 1001 | -------------------------------------------------------------------------------- About Affitech Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilises a range of proprietary antibody technologies for the discovery of therapeutic antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech A/S's premier technology platform for the isolation of lead antibodies to cell surface targets. Several of the Company's proprietary drug candidates were generated by CBAS™. Further information is available at www.affitech.com. Disclaimer This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products. No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.